Email this article Efficacy of 2-isobutyl-4,6-dimethyl-5-oxypyrimidine in monotherapy and in combination with doxorubicin on AKATOL colon cancer in mice
- Authors: Zhurikov R.V.1, Kovalenko L.P.1, Ivanova E.A.1, Vasilchuk A.G.1, Kolik L.G.1, Gudasheva T.A.1
-
Affiliations:
- Federal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies
- Issue: Vol 25, No 2 (2026)
- Pages: 81-88
- Section: ORIGINAL REPORTS
- Published: 15.07.2026
- URL: https://bioterapevt.abvpress.ru/jour/article/view/1541
- DOI: https://doi.org/10.17650/1726-9784-2026-25-2-81-88
- ID: 1541
Cite item
Open Access
Access granted
Subscription or Fee Access
Abstract
Background. Compounds capable of suppressing inflammation and modulating the antitumor immune response may enhance the effectiveness of cytostatic therapy. In this regard, the strategy of combined use of 2-isobutyl-4,6-dimethyl-5-oxypyrimidine with classical chemotherapy drugs is of particular interest.
Aim. Evaluation of 2-isobutyl-4,6-dimethyl-5-oxypyrimidine (base SNK-411 and salt SNK-578) per se or with doxorubicin on tumor growth inhibition and survival in the murine AKATOL colon adenocarcinoma model.
Materials and methods. Antitumor activity of 2-isobutyl-4,6-dimethyl-5-oxypyrimidine was studied in tests on BALB / c mice using the AKATOL colon adenocarcinoma model. A standard graft of 1 × 106 AKATOL tumor cells was administered to each mouse. Starting on day 2, mice received treatment with SNK-578 (10 mg / kg, intraperitoneal) or SNK-411 per os (25 mg / kg) or their combinations with doxorubicin daily. A positive control group received doxorubicin (5 mg / kg, intraperitoneal) on days 2 and 4. The endpoints for assessing antitumor activity were the percentage of tumor growth inhibition (TGI) and increase in lifespan.
Results. Monotherapy with SNK-411 and SNK-578 showed high efficacy (TGI ~74 % on day 21). Doxorubicin showed similar efficacy (inhibition of tumor growth 82 %), however, in this group, the death of 2 out of 12 animals was recorded. The combination therapy surpassed the monotherapy with doxorubicin in terms of tumor growth suppression and did not cause the death of animals. The increase in lifespan in the SNK-411 and SNK-578 groups was 31 and 33 %, respectively.
Conclusion. Base SNK-411 and salt SNK-578 show antitumor activity and synergize with doxorubicin, reducing its toxicity. These results corroborate earlier data from cervical cancer RSHM-5 and Lewis lung carcinoma models.
About the authors
Ruslan V. Zhurikov
Federal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies
Author for correspondence.
Email: zhurikovrv@gmail.com
ORCID iD: 0000-0003-1084-690X
Russian Federation, 8 Baltiyskaya St., Moscow 125315
Larisa P. Kovalenko
Federal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies
Email: zhurikovrv@gmail.com
ORCID iD: 0000-0002-2083-0832
Russian Federation, 8 Baltiyskaya St., Moscow 125315
Elena A. Ivanova
Federal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies
Email: zhurikovrv@gmail.com
ORCID iD: 0000-0003-4961-2051
Russian Federation, 8 Baltiyskaya St., Moscow 125315
Anastasia G. Vasilchuk
Federal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies
Email: zhurikovrv@gmail.com
ORCID iD: 0000-0002-9079-1322
Russian Federation, 8 Baltiyskaya St., Moscow 125315
Larisa G. Kolik
Federal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies
Email: zhurikovrv@gmail.com
ORCID iD: 0000-0002-9847-8058
Russian Federation, 8 Baltiyskaya St., Moscow 125315
Tatiana A. Gudasheva
Federal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies
Email: zhurikovrv@gmail.com
ORCID iD: 0000-0002-5185-4474
Russian Federation, 8 Baltiyskaya St., Moscow 125315
References
- Самотруева М.А., Цибизова А.А, Ясенявская А.Л. и др. Фармакологическая активность производных пиримидинов. Астраханский медицинский журнал 2015;1:12–29. Samotrueva M.A., Tsibizova A.A., Yasenevskaya A.L. et al. Pharmacological activity of pyrimidine derivatives. Astrakhanskiy meditsinskiy zhurnal = Astrakhan Medical Journal 2015;1:12–29. (In Russ.).
- Коваленко Л.П., Никитин С.В., Сорокина А.В. и др. Влияние 2-изобутил-4,6- диметил-5-оксипиримидина на рост и метастазирование карциномы легкого Lewis у мышей линии C57Bl/6. Экспериментальная и клиническая фармакология 2020;83(6):24–7. doi: 10.30906/0869-2092-2020-83-1-24-27 Kovalenko L.P., Nikitin S.V., Sorokina A.V. et al. Effect of 2-isobutyl-4,6-dimethyl-5-oxypyrimidine on growth and metastasis of Lewis lung carcinoma in C57BL/6 mice. Eksperimentalnaya y klinicheskaya farmakologiya = Experimental and clinical pharmacology 2020;83(6):24–7. (In Russ.). doi: 10.30906/0869-2092-2020-83-1-24-27
- Коржова К.В., Коваленко Л.П., Иванова Е.А. и др. Влияние производных 5-оксипиримидина на рост опухоли и продолжительность жизни мышей линии C57Bl/6 с эпидермоидной карциномой легких. Бюллетень экспериментальной биологии и медицины, 2020;169(2):226–9. doi: 10.1007/s10517-020-04864-z Korzhova K.V., Kovalenko L.P., Ivanova E.A. et al. Effect of 5-oxypyrimidine derivatives on tumour growth in and lifespan of C57Bl/6 mice with epidermoid lung carcinoma. Byulleten eksperimentalnoy biologii y meditsini = Bulletin of Experimental Biology and Medicine 2020;169(2):226–9. (In Russ.). doi: 10.1007/s10517-020-04864-z
- Журиков Р.В., Коваленко Л.П., Алексеева С.В. и др. Влияние производных 5-оксипиримидина на противоопухолевый эффект гемцитабина, гематологические показатели и продолжительность жизни у мышей с аденокарциномой Ca755. Вопросы онкологии 2023;69(2):238–45. doi: 10.37469/0507-3758-2023-69-2-238-245 Zhurikov R.V., Kovalenko L.P., Alexeeva S.V. et al. The effect of 5-hydroxypyrimidine derivatives on the antitumor effect of gemcitabine, hematological parameters, and survival of mice with adenocarcinoma Ca755. Voprosy Onkologii = Problems in Oncology 2023;69(2):238–45. doi: 10.37469/0507-3758-2023-69-2-238-245
- Коваленко Л.П., Коржова К.В., Зайнуллина Л.Ф. и др. Влияние производных 5-оксипиримидина на рост опухоли и содержание интерлейкинов в сыворотке крови самок мышей линии СВА с раком шейки матки (РШМ-5). Биомедицинская химия 2021;67(2):158–61. doi: 10.18097/pbmc20216702158 Kovalenko L.P., Korzhova K.V., Zainullina L.F. et al. Effect of 5-hydroxypyrimidine derivatives on tumor growth and cytokine concentration in blood serum of female CBA mice with cervical cancer (RSHM-5). Biomeditsinskaya khimiya = Biomedical Khim. 2021;67(2):158–61. (In Russ.). doi: 10.18097/pbmc20216702158
- Коваленко Л.П., Коржова К.В., Никитин С.В. и др. Коррекция уровня сывороточных проонкогенных цитокинов и метастазирования производными 5-оксипиримидина и доксорубицином после удаления первичного опухолевого узла у мышей с метастазирующим раком легкого LLC. Биомедицинская химия 2023;69(1):39–45. doi: 10.18097/PBMC20236901039 Kovalenko L.P., Korzhova K.V., Nikitin S.V. et al. Correction of serum prooncogenic cytokines and metastases by 5-hydroxypyrimidine derivatives and doxorubicin after removal of a primary tumor node in mice with the Lewis lung epidermoid carcinoma. Biomeditsinskaya khimiya = Biomed Khim. 2023;69(1):39–45. (In Russ.). doi: 10.18097/PBMC20236901039
- Коваленко Л.П., Журиков Р.В., Вальдман Е.А., Никитин С.В. Влияние производных 5-оксипиримидина и препарата сравнения Эриус на выраженность системной реакции анафилаксии, уровень иммуноглобулина Е (IgE) и цитокинов у мышей линии BALB/c. Медицинская иммунология 2024;26(6):1197–204. doi: 10.15789/1563-0625-EOH-2870 Kovalenko L.P., Zhurikov R.V., Valdman E.A., Nikitin S.V. Effect of 5-hydroxypyrimidine derivatives and reference drug Aerius on systemic anaphylaxis, concentration of immunoglobulin E and cytokines tested in Balb/c mice. Meditsinskaya immunologiya = Medical Immunology. 2024;26(6):1197–204. (In Russ.). doi: 10.15789/1563-0625-EOH-2870
- Журиков Р.В., Коваленко Л.П., Никитин С.В., Дурнев А.Д. Влияние производного 5-оксипиримидина на рост и метастазирование меланомы B16 у мышей линии С57BL/6. Российский биотерапевтический журнал 2021;20(3):66–72. doi: 10.17650/1726-9784-2021-20-3-66-72 Zhurikov R.V., Kovalenko L.P., Nikitin S.V., Durnev A.D. Effects of 5-hydroxypyrimidine derivative on growth and metastasis of melanoma b16 in c57bl/6 mice. Rossijskij bioterapevticeskij zurnal = Russian Journal of Biotherapy 2021;20(3):66–72. (In Russ.). doi: 10.17650/1726-9784-2021-20-3-66-72
- Коваленко Л.П., Никитин С.В., Дурнев А.Д., Гудашева Т.А. Средство с противоопухолевой, антиметастатической активностью, противовоспалительным и противоаллергенным действием. Патент РФ №2686672 C1, 30.04.2019. Бюл. №13. Kovalenko L.P., Nikitin S.V., Durnev A.D., Gudasheva T.A. Agent with antitumour and antimetastatic activity, anti-inflammatory and antiallergic action. RU 2686672 C1, 30.04.2019. Bull. No. 13. (In Russ.).
- Середенин С.Б., Никитин С.В., Коваленко Л.П., Дурнев А.Д. Производное 5-оксипиримидина, обладающее противоопухолевой активностью. Патент РФ №2518889 C2, 10.06.2014. Бюл. №16. Seredenin S.B, Nikitin S.V., Kovalenko L.P., Durnev A.D. 5-oxypyrimidine derivative possessing antineoplastic activity. RU 2518889 C2 10.06.2014. Bull. No. 16 (In Russ.).
- Song X., Traub B., Shi J., Kornmann M. Possible roles of interleukin-4 and -13 and their receptors in gastric and colon cancer. Int J Mol Sci 2021;22(2):727. doi: 10.3390/ijms22020727
- Трещалина Е.М., Жукова О.С., Герасимова Г.К. и др. Методические рекомендации по доклиническому изучению противоопухолевой активности лекарственных средств. В кн.: Руководство по проведению доклинических исследований лекарственных средств. Под ред. А.Н. Миронова и др. Ч. I. М.: Гриф и К., 2012. С. 642–57. Treshchalina E.M., Zhukova O.S., Gerasimova G.K. et al. Methodological recommendations for the preclinical study of the antitumor activity of drugs. In: Guidelines for conducting preclinical studies of medicines. Part I. Ed. by A.N. Mironov et al. Moscow: Grif i K, 2012. P. 642–57. (In Russ.).
- D’Arrigo G., Leonardis D., ElHafeez S.A. et al. Methods to analyse time-to-event data: The Kaplan–Meier survival curve. Oxid Med Cell Longev 2021;2021:2290120. doi: 10.1155/2021/2290120
- Birch R.J., Burr N., Subramanian V. et al. Inflammatory bowel disease-associated colorectal cancer epidemiology and outcomes: an English population-based study. Am J Gastroenterol 2022;117(11):1858–70. doi: 10.14309/ajg.0000000000001941
- Кузнецова О.С., Таллерова А.В., Никитин С.В., Коваленко Л.П. Иммунофармакологические свойства нового производного 5-оксипиримидина СНК-411. Экспериментальная и клиническая фармакология 2015;78(4):6–9. doi: 10.30906/0869-2092-2015-78-4-6-9 Kuznetsova O.S., Tallerova A.V., Nikitin S.V., Kovalenko L.P. Immunopharmacological properties of new 5-pyrimidinol derivative SNK-411. Eksperimentalnaya y klinicheskaya farmakologiya = Experimental and Clinical Pharmacology 2015; 78(4):6–9. (In Russ.). doi: 10.30906/0869-2092-2015-78-4-6-9
- Hou N., Zhang X., Zhao L. et al. A novel chronic stress induced shift in the Th1 to Th2 response promotes colon cancer growth. Biochem Biophys Res Commun 2013;439(4):471–6. doi: 10.1016/j.bbrc.2013.08.101
- Shamoun L., Skarstedt M., Andersson R.E. et al. Association study on IL-4, IL-4Ralpha and IL-13 genetic polymorphisms in Swedish patients with colorectal cancer. Clin Chim Acta 2018;487:101–6. doi: 10.1016/j.cca.2018.09.024
Supplementary files
